| D009500 |
Neutralization Tests |
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). |
Neutralization Test,Test, Neutralization,Tests, Neutralization |
|
| D003168 |
Complement Fixation Tests |
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1. |
Complement Absorption Test, Conglutinating,Conglutination Reaction,Conglutinating Complement Absorption Test,Complement Fixation Test,Conglutination Reactions,Fixation Test, Complement,Fixation Tests, Complement,Reaction, Conglutination,Reactions, Conglutination,Test, Complement Fixation,Tests, Complement Fixation |
|
| D003384 |
Coxsackievirus Infections |
A heterogeneous group of infections produced by coxsackieviruses, including HERPANGINA, aseptic meningitis (MENINGITIS, ASEPTIC), a common-cold-like syndrome, a non-paralytic poliomyelitis-like syndrome, epidemic pleurodynia (PLEURODYNIA, EPIDEMIC) and a serious MYOCARDITIS. |
Coxsackie Virus Infections,Infections, Coxsackie Virus,Infections, Coxsackievirus,Coxsackie Virus Infection,Coxsackievirus Infection |
|
| D005500 |
Follow-Up Studies |
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. |
Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup |
|
| D006385 |
Hemagglutination Inhibition Tests |
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination. |
Hemagglutination Inhibition Test,Inhibition Test, Hemagglutination,Inhibition Tests, Hemagglutination,Test, Hemagglutination Inhibition,Tests, Hemagglutination Inhibition |
|
| D006446 |
Hemoglobin E |
An abnormal hemoglobin that results from the substitution of lysine for glutamic acid at position 26 of the beta chain. It is most frequently observed in southeast Asian populations. |
|
|
| D006455 |
Hemoglobins, Abnormal |
Hemoglobins characterized by structural alterations within the molecule. The alteration can be either absence, addition or substitution of one or more amino acids in the globin part of the molecule at selected positions in the polypeptide chains. |
Abnormal Hemoglobins |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000914 |
Antibodies, Viral |
Immunoglobulins produced in response to VIRAL ANTIGENS. |
Viral Antibodies |
|
| D013789 |
Thalassemia |
A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. |
Thalassemias |
|